person · Reporting owner

Bertrand William C JR

Disclosed activity across 2 companies

Tapewire entity: 36785
SEC CIK: 0001291937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director	June 16, 2026	June 18, 2026
Adaptimmune Therapeutics PLCADAP · Entity 9824	Chief Operating Officer	August 28, 2025	August 29, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	329,507	Ending reported balance After 2026-06-16 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-16 · Grant · Acquired 12,345 · Balance 303,052 F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Row 2 · 2026-06-16 · Grant · Acquired 26,455 · Balance 329,507 F2: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16	Direct	39,715	Reported balance After 2026-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F3: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F4: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.

F2: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F4: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Adaptimmune Therapeutics PLC

Report date August 28, 2025 · Filed August 29, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares with a nominal value of GBP0.001 per shareSEC Table I · non-derivative	Direct	986,352	Reported balance After 2025-08-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-08-28 · Sale · Disposed 207,000 · Balance 986,352 F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer. F2: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs. F3: The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote. F4: The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.

F2: The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.

F3: The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F4: The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 16, 2020 Filed Jan 18, 2020 02:31 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	280,896	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-20-005258 · a4.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,896 Underlying: Ordinary Shares · 280,896 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023 and 70,224 Ordinary Shares on January 16, 2024. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document
January 16, 2020 Filed Jan 18, 2020 02:31 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	1,257,744	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0001104659-20-005258 · a4.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,744 Underlying: Ordinary Shares · 1,257,744 shares Expires 2030-01-16 F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024. Read SEC document
January 14, 2020 Filed Jan 16, 2020 01:03 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares representing Ordinary Shares	2,397	$5.13	$12,307.88	Disclosure SEC source: 0001104659-20-004423 · a4.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,605 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,363ADSs and RSU-style options and other options covering an aggregate of 5,299,674 ordinary shares of the Issuer. Read SEC document
January 06, 2020 Filed Jan 8, 2020 01:01 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares representing Ordinary Shares	3,731	$1.20	$4,477.20	Disclosure SEC source: 0001104659-20-002081 · a4.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,632 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,731 ADSs and RSU-style options and other options covering an aggregate of 5,335,686 ordinary shares of the Issuer Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:31 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001567619-19-013481 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:31 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	18,248	$0.00	$0.00	Disclosure SEC source: 0001567619-19-013481 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,135 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document
January 14, 2019 Filed Jan 17, 2019 02:31 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	SaleAmerican Depositary Shares representing Ordinary Shares	2,271	$5.37	$12,193.91	Disclosure SEC source: 0001104659-19-002165 · a4.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 5,391,864 ordinary shares of the Issuer. Read SEC document
January 04, 2019 Filed Jan 9, 2019 02:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	224,724	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-19-001304 · a4.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,724 Underlying: Ordinary Shares · 224,724 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document
January 04, 2019 Filed Jan 9, 2019 02:02 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	1,006,224	$0.00 Strike: $0.89	$0.00	Disclosure SEC source: 0001104659-19-001304 · a4.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,224 Underlying: Ordinary Shares · 1,006,224 shares Expires 2029-01-04 F1 · derivative.exercise_price: The exercise price was converted from GBP0.70 based on an exchange rate of $U.S. 1.26332 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023. Read SEC document
June 13, 2018 Filed Jun 15, 2018 22:57 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.03	$0.00	Disclosure SEC source: 0001140361-18-028863 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
June 13, 2018 Filed Jun 15, 2018 22:57 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	12,406	$0.00	$0.00	Disclosure SEC source: 0001140361-18-028863 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,887 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document
January 12, 2018 Filed Jan 17, 2018 22:20 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	144,048	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-18-002675 · a4.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,048 Underlying: Ordinary Shares · 144,048 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 36,012 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 36,012 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document
January 12, 2018 Filed Jan 17, 2018 22:20 UTC	Adaptimmune Therapeutics PLC ADAP · Entity 9824	GrantOption to purchase Ordinary Shares · Derivative	644,976	$0.00 Strike: $1.30	$0.00	Disclosure SEC source: 0001104659-18-002675 · a4.xml · derivative · entry 1 Bertrand William C JR · CIK 0001291937 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,976 Underlying: Ordinary Shares · 644,976 shares Expires 2028-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 161,244 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 13,437 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. Read SEC document
June 07, 2017 Filed Jun 9, 2017 23:05 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001140361-17-024618 · doc1.xml · derivative · entry 2 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-07 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
June 07, 2017 Filed Jun 9, 2017 23:05 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	11,627	$0.00	$0.00	Disclosure SEC source: 0001140361-17-024618 · doc1.xml · nonDerivative · entry 1 Bertrand William C JR · CIK 0001291937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,481 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.